These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15295043)

  • 21. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism.
    Poggio R; Grancelli HO; Miriuka SG
    Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Slow adoption of helpful heart failure drug. Many people who could benefit from spironolactone aren't getting it.
    Harv Heart Lett; 2010 Feb; 20(6):2. PubMed ID: 20376944
    [No Abstract]   [Full Text] [Related]  

  • 24. [Urea and spironolactone therapy].
    Schwarzbach W; Bunzl W
    Munch Med Wochenschr; 1973 Jan; 115(3):76-80. PubMed ID: 4739290
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C; Donker AJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1724-6. PubMed ID: 10494316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of aldosterone blockade in end-stage renal disease.
    Pitt B; Saran R
    Cardiology; 2009; 114(1):30-1. PubMed ID: 19342856
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
    Barbour MM; Zuwallack A
    Med Health R I; 2001 Feb; 84(2):55-8. PubMed ID: 11272661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of diuretics and aldosterone antagonists in the treatment of heart failure].
    Schwinger RH
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S40-7. PubMed ID: 10535046
    [No Abstract]   [Full Text] [Related]  

  • 29. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ; Pfeffer MA; Swedberg K; Dzau VJ
    Circulation; 2004 Nov; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract]   [Full Text] [Related]  

  • 30. Spironolactone in patients with heart failure.
    Vanpee D; Swine C
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF; Overdiek JW; van Veldhuisen DJ
    Ned Tijdschr Geneeskd; 2001 Feb; 145(5):204-8. PubMed ID: 11219145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of the RALE study. Hyperkalemia following spironolactone treatment].
    Erdmann E
    Internist (Berl); 2005 Apr; 46(4):466, 468. PubMed ID: 15723149
    [No Abstract]   [Full Text] [Related]  

  • 33. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson's disease and congestive heart failure.
    Teive HA; Munhoz RP; Werneck LC
    Mov Disord; 2007 Aug; 22(11):1678-9. PubMed ID: 17534964
    [No Abstract]   [Full Text] [Related]  

  • 34. What's old is new again. Spironolactone and heart failure.
    Lock M; Chun R
    Can Fam Physician; 1999 Nov; 45():2621-2. PubMed ID: 10587769
    [No Abstract]   [Full Text] [Related]  

  • 35. [Finely adjusted differential therapy succeeds this way! References for dose adjustments in heart failure (interview by Dr. Dirk Einecke)].
    Erdmann E
    MMW Fortschr Med; 2005 Sep; 147(39):11. PubMed ID: 16245770
    [No Abstract]   [Full Text] [Related]  

  • 36. [Spironolactone as a cardio-protective drug].
    Yoshimura M
    Nihon Rinsho; 2007 May; 65 Suppl 5():107-9. PubMed ID: 17569309
    [No Abstract]   [Full Text] [Related]  

  • 37. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Acute reversible kidney insufficiency due to enalapril during diuretic-treated heart insufficiency].
    Degenhardt S
    Dtsch Med Wochenschr; 1987 Jun; 112(24):960-3. PubMed ID: 3036457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
    Wrenger E; Müller R; Moesenthin M; Welte T; Frölich JC; Neumann KH
    BMJ; 2003 Jul; 327(7407):147-9. PubMed ID: 12869459
    [No Abstract]   [Full Text] [Related]  

  • 40. Eplerenone and chronic heart failure. No comparison with spironolactone.
    Prescrire Int; 2013 Jun; 22(139):148-9. PubMed ID: 23866347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.